نتایج جستجو برای: rilpivirine

تعداد نتایج: 396  

2017
David A Wohl Rima Kulkarni Will Garner Kirsten White Danielle Porter

State University, Columbus, Ohio, Capital Medical Associates, Washington DC, DC, The Dr James J Rahal Jr. Division of Infectious Disease, NewYork-Presbyterian Queens, Flushing, New York, La Playa Medical Group, San Diego, California, AIDS Healthcare Foundation, Los Angeles, California, APEX Research, Denver, Colorado, Atlanta Infectious Disease Group PC, Atlanta, Georgia, Gilead Sciences, Foste...

Journal: :The Journal for Nurse Practitioners 2022

There have been significant developments in effective human immunodeficiency virus treatment since the first antiretroviral was approved. A number of people living with not able to maintain viral suppression on oral therapy. long-acting monthly injectable regimen consisting cabotegravir and rilpivirine has approved for individuals who are virally suppressed. This is a good option those struggle...

2015
Markus Hecht Sonja Erber Thomas Harrer Hartwig Klinker Thomas Roth Hans Parsch Nora Fiebig Rainer Fietkau Luitpold V. Distel Luis Menéndez-Arias

BACKGROUND Cancer prevention and therapy in HIV-1-infected patients will play an important role in future. The non-nucleoside reverse transcriptase inhibitors (NNRTI) Efavirenz and Nevirapine are cytotoxic against cancer cells in vitro. As other NNRTIs have not been studied so far, all clinically used NNRTIs were tested and the in vitro toxic concentrations were compared to drug levels in patie...

2016
Thomas Whitfield Adele Torkington Clare van Halsema

Modern antiretroviral therapy has demonstrated effectiveness in preexposure prophylaxis (PrEP) and treatment of HIV infection. There is a demand for prevention and treatment regimens that could overcome challenges of improving adherence, toxicity, and dosing convenience. Cabotegravir is an integrase strand transfer inhibitor and an analog of dolutegravir. Unlike dolutegravir, cabotegravir has a...

Journal: :Antimicrobial agents and chemotherapy 2015
Laura Dickinson H Manisha Yapa Akil Jackson Graeme Moyle Laura Else Alieu Amara Saye Khoo David Back Zeenat Karolia Chris Higgs Marta Boffito

Pharmacokinetic (PK) data describing a prolonged time course of antiretrovirals in plasma and peripheral blood mononuclear cells (PBMCs) are important for understanding and managing late or missed doses and to assess the appropriateness of compounds for preexposure prophylaxis (PrEP). This study aimed to evaluate the PK of coformulated tenofovir disoproxil fumarate (DF), emtricitabine, and rilp...

Journal: :Drug discovery today 2008
Jens van Roey Tido von Schoen-Angerer Nathan Ford Alexandra Calmy

Clinical trials are usually designed to meet registration requirements in developed countries, and do not always address key concerns for use in developing countries. Four late-stage investigational new drugs - rilpivirine, etravirine, raltegravir and maraviroc - show potential to improve antiretroviral therapy. However, a number of issues could limit their use in developing countries, includin...

Journal: :The Journal of antimicrobial chemotherapy 2013
Lourdes Anta José L Blanco Josep M Llibre Federico García María J Pérez-Elías Antonio Aguilera Pilar Pérez-Romero Estrella Caballero Carmen Vidal Angelina Cañizares Félix Gutiérrez David Dalmau José A Iribarren Vicente Soriano Carmen de Mendoza

OBJECTIVES Limited data are available on resistance to etravirine, rilpivirine, darunavir and tipranavir in patients infected with HIV-1 non-B subtypes, in which natural polymorphisms at certain positions could influence the barrier and/or pathways to drug resistance. METHODS FASTA format sequences from the reverse transcriptase and protease genes recorded within the Spanish Drug Resistance d...

Journal: :The Lancet. Infectious diseases 2015
David A Margolis Cynthia C Brinson Graham H R Smith Jerome de Vente Debbie P Hagins Joseph J Eron Sandy K Griffith Marty H St Clair Marita C Stevens Peter E Williams Susan L Ford Britt S Stancil Melinda M Bomar Krischan J Hudson Kimberly Y Smith William R Spreen

BACKGROUND In phase 1 trials, the HIV-1 integrase strand transfer inhibitor cabotegravir (GSK1265744) was well tolerated, both alone, and in combination with the non-nucleoside reverse transcriptase inhibitor rilpivirine. We assessed cabotegravir plus rilpivirine, as a two-drug oral antiretroviral regimen, for the maintenance of viral suppression in antiretroviral-naive HIV-1-infected individua...

Journal: :Journal of Antimicrobial Chemotherapy 2012

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید